Vanguard Group Inc. Purchases 10,119 Shares of Haemonetics Co. (NYSE:HAE)

Vanguard Group Inc. increased its position in Haemonetics Co. (NYSE:HAE) by 0.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,179,388 shares of the medical instruments supplier’s stock after purchasing an additional 10,119 shares during the period. Vanguard Group Inc. owned approximately 10.31% of Haemonetics worth $404,407,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of HAE. FMR LLC lifted its stake in shares of Haemonetics by 206.3% in the third quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier’s stock valued at $62,257,000 after buying an additional 521,640 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Haemonetics by 9.5% in the 3rd quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier’s stock worth $337,722,000 after acquiring an additional 363,702 shares during the last quarter. Raymond James Financial Inc. bought a new position in Haemonetics in the 4th quarter valued at about $19,002,000. Thrivent Financial for Lutherans boosted its stake in Haemonetics by 14.9% during the 4th quarter. Thrivent Financial for Lutherans now owns 1,264,294 shares of the medical instruments supplier’s stock valued at $98,716,000 after purchasing an additional 164,111 shares during the last quarter. Finally, Boston Partners increased its holdings in Haemonetics by 27.5% during the 4th quarter. Boston Partners now owns 536,262 shares of the medical instruments supplier’s stock worth $41,485,000 after purchasing an additional 115,506 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Trading Up 1.7 %

NYSE:HAE opened at $64.09 on Thursday. Haemonetics Co. has a 12 month low of $58.80 and a 12 month high of $97.97. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. The firm’s 50 day moving average is $65.42 and its 200 day moving average is $74.47. The stock has a market capitalization of $3.22 billion, a PE ratio of 25.23, a price-to-earnings-growth ratio of 1.11 and a beta of 0.43.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Sell-side analysts expect that Haemonetics Co. will post 4.55 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Needham & Company LLC dropped their target price on Haemonetics from $108.00 to $104.00 and set a “buy” rating on the stock in a report on Tuesday, March 18th. StockNews.com downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Saturday, February 15th. JPMorgan Chase & Co. started coverage on shares of Haemonetics in a report on Friday, December 6th. They issued an “overweight” rating and a $116.00 target price for the company. Barrington Research cut their price target on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Finally, Raymond James reaffirmed a “strong-buy” rating and issued a $115.00 price objective (down from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Haemonetics currently has an average rating of “Moderate Buy” and an average price target of $101.22.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.